Implementation of Decree No. 818: Filing Is Not a Green Light for Clinical Application, Technology Translation Still Needs Regulatory Definition

May 01,2026

Several Insights by Wu Zhaohui, Vice Chairman of China Association of Pharmaceutical Biotechnology

CPIC 2026丨Cellgenes Biotechnology Special Symposium: Patient-Centric Innovation in Stem Cell Drug R&D

Apr 30,2026

Lead China's innovative stem cell drugs to the global frontier

Domestic Autoimmune Drugs Begin to Shine

Apr 30,2026

Open the door to a hundred-billion-dollar market

国产自免药,初露锋芒

Apr 30,2026

叩开千亿美元级市场

CPIC 2026 | Agenda Released: International Advanced Drug Delivery Systems & Combination Products

Apr 29,2026

Planned by Yianshi Medical Technology, and supported by Wanhai Medical & Aptar Pharmaceuticals.

In vivo CAR-T: Is there a growing shortage of target antigens?

Apr 29,2026

Chinese enterprises are emerging as an undeniable force.

CPIC 2026 | Conference Blueprint 2.0 Released: Who Is Co-organizing with Us?

Apr 28,2026

Conference Blueprint 2.0 is officially released. This is an open invitation to the global pharmaceutical industry to co-create.

CPIC 2026 | Fangda Partners Special Session: Legal Safeguards and Value Empowerment for the Globalization of Chinese Pharmaceutical Enterprises

Apr 28,2026

Fangda Partners' Life Sciences teams and TONACEA are jointly hosting a special session themed "Legal Safeguards and Value Empowerment for the Globalization of Chinese Pharmaceutical Enterprises," focusing on cutting-edge legal issues in the pharmaceutical sector.
< 1...181920...26 > proceed page